ERAS - Erasca - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

325.1M

Cash

297.7M

Avg Qtr Burn

-27.03M

Short % of Float

19.07%

Insider Ownership

14.72%

Institutional Own.

57.86%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Naporafenib (pan-RAF inhibitor) w/ trametinib Details NRASm melanoma, Melanoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Naporafenib (pan-RAF inhibitor) w/ trametinib Details Solid tumor/s, RAS Q61X solid tumors	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ERAS-007 w/ encorafenib and cetuximab Details Cancer, Advanced malignancies, Gastrointestinal stromal tumors, Colorectal cancer , BRAFm Colorectal Cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ERAS-801/EGFR inhibitor Details Cancer, Glioblastoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ERAS-007 + ERAS-601 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ERAS-601 (SHP2 inhibitor) Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ERAS-007 Details Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.